ArticleEuropean radiology2025
Post-processing steps improve generalisability and robustness of an MRI-based radiogenomic model for human papillomavirus status prediction in oropharyngeal cancer.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- HPV Detection in Oropharyngeal Cancer: A Narrative Review of Diagnostic and Emerging Molecular Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- Radiogenomics and machine learning in hepatocellular carcinoma: from foundations to clinical translation.World journal of surgical oncology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the impact of image post-processing steps on the generalisability of MRI-based radiogenomic models. Using a human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma (OPSCC) prediction model, this study examines the potential of different post-processing strategies to increase its generalisability across data from different centres and image acquisition protocols. MATERIALS AND
methodsContrast-enhanced T1-weighted MR images of OPSCC patients of two cohorts from different centres, with confirmed HPV status, were manually segmented. After radiomic feature extraction, the HPV prediction model trained on a training set with 91 patients was subsequently tested on two independent cohorts: a test set with 62 patients and an externally derived cohort of 157 patients. The data processing options included: data harmonisation, a process to ensure consistency in data from different centres; exclusion of unstable features across different segmentations and scan protocols; and removal of highly correlated features to reduce redundancy.
resultsThe predictive model, trained without post-processing, showed high performance on the test set, with an AUC of 0.79 (95% CI: 0.66-0.90, p < 0.001). However, when tested on the external data, the model performed less well, resulting in an AUC of 0.52 (95% CI: 0.45-0.58, p = 0.334). The model's generalisability substantially improved after performing post-processing steps. The AUC for the test set reached 0.76 (95% CI: 0.63-0.87, p < 0.001), while for the external cohort, the predictive model achieved an AUC of 0.73 (95% CI: 0.64-0.81, p < 0.001).
conclusionsWhen applied before model development, post-processing steps can enhance the robustness and generalisability of predictive radiogenomics models. KEY POINTS: Question How do post-processing steps impact the generalisability of MRI-based radiogenomic prediction models? Findings Applying post-processing steps, i.e., data harmonisation, identification of stable radiomic features, and removal of correlated features, before model development can improve model robustness and generalisability. Clinical relevance Post-processing steps in MRI radiogenomic model generation lead to reliable non-invasive diagnostic tools for personalised cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.